

Home monitoring with technology-supported management in chronic heart failure: A randomised trial

SUPPORT-HF 2 Investigators and Committees

Kazem Rahimi, Milad Nazarzadeh, Ana-Catarina Pinho-Gomes, Mark Woodward, Reza Khorshidi, Toshiaki Ohkuma, Raymond Fitzpatrick, Lionel Tarassenko, Mike Denis, John Cleland

Supplementary Table 1. Individual treatment opportunities and adherence to them at the beginning and end of the trial, by randomized treatment group.

Class of medications	Enhanced self-management (control)												Supported medical management (intervention)															
	Reduced EF (N=61)								Preserved EF (N=40)				Reduced EF (N=62)						Preserved EF (N=39)									
	TNO	Baseline		After six months				TNO	Baseline		After six months		TNO	Baseline		After six months				TNO	Baseline		After six months					
		N ₀	Sum ₀	N ₆	Sum ₆	Death	Censoring		N ₀	Sum ₀	N ₆	Sum ₆		Death	Censoring	N ₀	Sum ₀	N ₆	Sum ₆		Death	Censoring	N ₀	Sum ₀	N ₆	Sum ₆	Death	Censoring
Beta-blocker	45	39	19.25	42	19	1	0	17	NA	NA	NA	NA	54	47	25.00	49	31.88	1	1	16	NA	NA	NA	NA				
ACE-I or ARB or ARN-I	47	43	19.50	41	23.30	1	0	17	NA	NA	NA	NA	54	44	24.34	46	32.33	0	2	17	NA	NA	NA	NA				
Mineralocorticoid Receptor Antagonist	49	32	23.32	33	24.50	1	0	15	NA	NA	NA	NA	52	30	26.05	33	29.30	0	1	11	NA	NA	NA	NA				
Hydralazine/Nitrate	1	1	NA	1	NA	0	0	0	NA	NA	NA	NA	1	1	NA	1	NA	0	0	0	NA	NA	NA	NA				
Ivabradine	2	2	NA	2	NA	0	0	0	NA	NA	NA	NA	1	1	NA	1	NA	0	0	0	NA	NA	NA	NA				
Digoxin	4	4	NA	4	NA	0	0	0	NA	NA	NA	NA	2	1	NA	1	NA	0	0	0	NA	NA	NA	NA				
Aspirin	15	10	NA	11	NA	0	0	20	13	NA	11	NA	1	2	13	11	NA	12	NA	0	0	10	10	NA	7	NA	2	1
Oral anticoagulation	30	21	NA	28	NA	1	1	19	14	NA	16	NA	0	1	33	21	NA	26	NA	1	1	16	9	NA	13	NA	1	1
High-dose statin †	NA	NA	NA	NA	NA			28	14	NA	13	NA	0	2	NA	NA	NA	NA	NA			21	7	NA	7	NA	2	2

EF: Ejection Fraction, N: total sample size; TNO: total number of opportunity at randomisation; N₀: number of who have fulfilled the opportunity at baseline; Sum₀: sum of fraction of recommended daily dose at baseline; N₆: number of who have fulfilled the opportunity after six months; Sum₆: sum of fraction of recommended daily dose after six months; Censoring: loss to follow up

† High-dose statin: Atorvastatin 40 mg or more, Rosuvastatin 10 mg or more, Simvastatin 80 mg or more, or a combination of a statin with Ezetimibe.